Skip to main content
. 2021 Jun 22;12:609148. doi: 10.3389/fphar.2021.609148

FIGURE 1.

FIGURE 1

(A) BCVA of treatment-Naïve patients with BU retinal vasculitis in the CT group and ADA group at monthly regular visits. (B) Daily glucocorticoid dosage of patients in the CT group and ADA group at monthly regular visits and at final follow-up. In CT group, 20 (83.3%) patients proceeded oral glucocorticoid with dose of 22.63 ± 20.83 mg/d, while in ADA group, 11 (53.4%) patients proceeded oral glucocorticoid with dose of 7.50 ± 2.96 mg/d. (C) A 10-year-old female BU patient with a BCVA of 0.4 (OD) and 0.16 (OS). FA imaging (10 min) showed (C-left panel) severe “fern-like” pattern change and (C-right panel) OCT scan observed edema in the macula with thicknesses of 277 and 483 μm in the right (top) and left (bottom) eyes, respectively. (D-left panel) FA imaging (10 min) of the same patient after ADA administration at the 5-months follow-up shows signs of vasculitis disappearance. The BCVA of the patient improved to 0.63 (OD) and 0.63 (OS). (D-right panel) Normalization of morphology in macular region in OCT scan after ADA treatment.